Jon Snow, the veteran broadcaster, has revealed he is living with Alzheimer’s disease, a diagnosis that throws a stark light on a condition affecting an estimated one million people in the UK. The news, announced on Friday by the Alzheimer’s Society, places Snow among the millions whose lives are touched by dementia, the country’s biggest killer. Alzheimer’s disease accounts for 60 to 80 per cent of all dementia cases, a figure set to grow as the population ages: the number of people living with dementia in the UK is projected to reach 1.4 million by 2040.
Snow, 79, received his diagnosis in 2023 and has kept his battle private until now. He has a long-standing connection to the disease: his mother was diagnosed with Alzheimer’s in her late seventies and died over a decade later after a long decline. That experience led Snow to speak openly about the realities of being a carer and the search for appropriate care. He has also been a supporter of Alzheimer’s Research UK for years, taking part in initiatives including their virtual reality project “A Walk Through Dementia.” More recently, Snow participated in a clinical trial for the disease, reportedly joining research aimed at slowing its progression. He will share more about his own experience in an upcoming Channel 4 documentary, Jon Snow: A Last Big Story, airing on June 20, 2026. Despite the diagnosis, Snow has expressed some doubt, questioning whether he truly has the condition and noting that he does not feel “disabled in any way,” attributing his symptoms perhaps to typical ageing. His wife, Precious, has observed that friends had been asking about his wellbeing and that she had been concealing his struggles. Following his retirement in 2021, Snow suffered severe depression and became isolated, a period that may have masked or complicated the early signs.
Understanding Alzheimer’s disease
Alzheimer’s is a physical illness that progressively damages the brain, according to the Alzheimer’s Society. It is the most common cause of dementia, a broader term for the decline in memory, thinking skills and other cognitive abilities that profoundly affect daily life. The precise trigger remains elusive, but the disease is believed to stem from the abnormal accumulation of proteins — specifically amyloid and tau — in and around brain cells. These proteins form plaques and tangles that disrupt brain cell function and lead to brain shrinkage. This process can begin years before symptoms become noticeable.
The NHS notes that while the exact cause is not fully understood, risk factors include family history and lifestyle elements linked to cardiovascular disease. Age is the single most significant factor: the likelihood of developing Alzheimer’s roughly doubles every five years after the age of 65. However, the condition can affect younger people. Around one in 20 individuals with Alzheimer’s are under 65, a form known as early- or young-onset Alzheimer’s. In these cases, genetic mutations that increase amyloid-beta (Aβ) are known to trigger the disease. Recent research suggests Alzheimer’s may arise not just from plaque formation but from one protein interfering with the normal job of another — specifically, amyloid-beta competing with tau for binding sites on microtubules. Another line of investigation focuses on stalled protein processing linked to mutations in the presenilin-1 (PSEN1) gene.
The condition is named after Dr Alois Alzheimer, a German psychiatrist and neuropathologist who first described it in 1906 after examining a patient named Auguste D. She had experienced memory loss, disorientation and hallucinations. Post-mortem examination revealed senile plaques and neurofibrillary tangles in her brain — the hallmarks still used to diagnose the disease today. Dr Alzheimer’s colleague, Emil Kraepelin, later gave the disease its name in 1910.
How the disease progresses
The symptoms of Alzheimer’s unfold gradually, and their progression varies from person to person. Initial signs often include memory difficulties — particularly forgetting recent events or conversations — along with mood shifts and challenges with thinking and reasoning. People may struggle to find the right words, make decisions or plan ahead. These early changes can be subtle and are sometimes mistaken for normal ageing, but dementia is not a normal part of growing older.
As the disease advances, symptoms escalate. Confusion becomes more frequent, and individuals may become disoriented in familiar surroundings, losing their way in places they have known for years. Disrupted sleep patterns are common, with restlessness and wandering at night. Difficulty planning or making decisions can lead to problems with finances, cooking or managing medication. The NHS highlights that hallucinations — seeing or hearing things that are not there — and delusions — believing things that are untrue — may occur and can worsen over time.
In the later stages, the impact on speech and language becomes more pronounced. This condition, known as aphasia, can make it hard for the person to express themselves or understand others. Mobility also declines, with difficulty walking, moving or maintaining balance. Self-care tasks such as washing, dressing and eating become challenging. Behavioural and personality changes are common: some individuals become increasingly aggressive, demanding or suspicious of those around them. Others may withdraw, become apathetic or show uncharacteristic mood swings.
For those with young-onset Alzheimer’s — diagnosed before 65 — the symptoms can manifest differently. Memory loss is less likely to be the earliest sign. Instead, younger people may first experience problems with language, vision or behaviour. In some cases, movement difficulties or significant personality changes appear before cognitive decline becomes obvious. The average life expectancy after symptom onset is eight to ten years, according to the Alzheimer’s Society, though this can vary widely depending on age, general health and access to care.
Treatment and support options
There is currently no cure for Alzheimer’s disease. Medications are available to help manage symptoms such as anxiety, depression and pain, but they do not halt the underlying damage. In recent years, disease-modifying treatments have been developed that target the amyloid protein build-up. Lecanemab (brand name Leqembi) and donanemab have both received regulatory attention; lecanemab has been given a final recommendation by NICE for potential NHS availability, though this is under review. Clinical trials continue to explore drugs aimed at slowing progression, preventing the disease and targeting tau protein. Research is also investigating lifestyle factors: studies suggest that Mediterranean and MIND diets, rich in green leafy vegetables, may be associated with lower accumulation of abnormal proteins in the brain.
The financial and emotional toll of dementia is enormous. The cost of dementia in the UK is estimated at £42 billion in 2024 and is projected to rise to £90 billion by 2040. Around 63 per cent of this cost is borne by patients and their families, not the state. The average lifetime cost of dementia care per person is estimated at £100,000. Families often find their roles shift abruptly as partners or children become primary caregivers. Carers can experience intense emotional and physical stress, feelings of neglect, resentment, guilt and social isolation.
Support is available. Organisations such as the Alzheimer’s Society offer a Dementia Support Line, online forums and a wide range of information and advice for both people with dementia and their carers. For those affected — whether directly or through a loved one — seeking help early can make a significant difference in navigating the long journey ahead.
